Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;160(5):594-596.
doi: 10.1001/jamasurg.2025.0001.

Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes

Vasundhara Mathur  1 , Katherine Wasden  1 , Thomas H Shin  1 , Pourya Medhati  1 , Abdelrahman A Nimeri  1 , Ali Tavakkoli  1 , Eric G Sheu  1
Affiliations

Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes

Vasundhara Mathur et al. JAMA Surg. .
No abstract available

Plain language summary

This case-control study examines the use of glucagon-like peptide-1 receptor agonist before metabolic and bariatric surgery and its postoperative outcome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Nimeri reported being an advisory board member for Ethicon outside the submitted work. Dr Tavakkoli reported being cofounder and consultant for AltrixBio during the conduct of the study. Dr Sheu reported receiving personal fees from Cine-Med and Vicarious Surgical, nonfinancial support from Intuitive Surgical, and grants from National Institutes of Health outside the submitted work; holding 3 pending patents for CA7S and related pathways for treatment of obesity and diabetes. No other disclosures were reported.

References

    1. Wilding JPH, Batterham RL, Calanna S, et al. ; STEP 1 Study Group . Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 - DOI - PubMed
    1. Cunningham JG, Szoka N, Tabone LE, Cox S, Aylward L, Abunnaja S. Preoperative and early adjuvant weight loss medications in bariatric surgery patients with body mass index over 60 or suboptimal initial response to surgery. Surg Obes Relat Dis. 2023;19(8):832-840. doi:10.1016/j.soard.2023.01.021 - DOI - PubMed
    1. Bonnet JB, Tournayre S, Anitcheou J, et al. . Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery. Obesity (Silver Spring). 2024;32(1):50-58. doi:10.1002/oby.23922 - DOI - PubMed
    1. Ilanga M, Heard JC, McClintic J, et al. . Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study. Surg Endosc. 2023;37(12):9509-9513. doi:10.1007/s00464-023-10387-1 - DOI - PubMed
    1. Fadel MG, Fehervari M, Lairy A, et al. . Clinical outcomes of single-stage versus two-stage laparoscopic Roux-en-y gastric bypass in the management of obesity (BMI ≥ 50 kg/m2): a retrospective cohort study. Langenbecks Arch Surg. 2022;407(8):3349-3356. doi:10.1007/s00423-022-02664-9 - DOI - PMC - PubMed

LinkOut - more resources